Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;51(1):15-9.
doi: 10.3233/JAD-150915.

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study

Affiliations

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study

Assaf Shelef et al. J Alzheimers Dis. .

Abstract

Background: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).

Objective: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).

Methods: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.

Results: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.

Conclusion: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.

Keywords: Alzheimer’s disease; behavioral and psychological symptoms of dementia; cannabis; tetrahydrocannabinol.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

LinkOut - more resources

Feedback